<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740116</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT nr 2006-006714-14</org_study_id>
    <nct_id>NCT00740116</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid in Surgery of Advanced Ovarian Cancer</brief_title>
  <official_title>Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Preben Kjolhede</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Linkoeping</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if a standardized single dose tranexamic acid given
      intravenously immediately preoperatively reduces the perioperative bleeding volume and
      reduces the need of blood transfusion in women undergoing surgery for advanced ovarian
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perioperative bleeding volume</measure>
    <time_frame>From start of operation to discharge from hospital</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients receiving blood transfusions and number of transfusions</measure>
    <time_frame>start of operation to discharge from hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically or radiologically verified thromboembolic events within 5 week postoperatively</measure>
    <time_frame>From time of operation to 5 weeks postoperatively.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tranexamic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% NaCl solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>Tranexamic acid, 100 mg/ml; 15 mg/kg body weight added to 100 ml 0.9% NaCl solution given as a single dose intravenously immediately prior to scin incision at surgery</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cyklokapron, ATC-code: B02AA02</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% NaCl solution</intervention_name>
    <description>0.9% NaCl solution; 0.15 ml/kg body weight added to 100 ml 0.9% NaCl solution. The volume is given intravenously immediate before scin incision at surgery.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Natriumklorid lösning; ATC-code: B05BB01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females ages 18 or older with a pelvic or abdominal tumor suspected or
             histopathologically proven ovarian cancer FIGO stage II-IV who are undergoing primary
             surgery with the intention of performing optimal cytoreductive radical surgery.

          -  Understand and speak Swedish

          -  Accept participation in the study after written and verbal information and sign
             informed consent.

        Exclusion Criteria:

          -  Allergy to tranexamic acid

          -  Having had tranexamic acid within the recent 30 days

          -  Previous or present episode of thromboembolic events .

          -  Previous or present treatment within the recent 3 months with anticoagulant.

          -  Previous or present known coagulopathy

          -  Myocardial infarction within the previous 12 months or instable angina pectoris which,
             according to the investigator, may increase the risk for complications significantly
             in case of a lowering of the hemoglobin.

          -  Significant renal failure with serum-creatinine &gt; 250 µmol/l.

          -  Severe psychiatric dysfunction or mentally substantially disabled.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulf Leandersson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Obstetrics and Gynecology, Kalmar Central Hospital, 391 85 Kalmar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laila Falknäs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Obstetrics and Gynecology, Ryhov Central Hospital, 58185 Jönköping</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Preben Kjölhede, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Obstetrics and Gynecology, University Hospital, Linköping</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Torsten Johansson, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Orthopedic Surgery, University Hospital, 58185 Linköping Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helena Zachrisson, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept of Physiology, University Hospital, 58185 Linköping Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept of Obstetric and Gynecology, Ryhov Central Hospital</name>
      <address>
        <city>Jönköping</city>
        <zip>55185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Kalmar Central Hospital</name>
      <address>
        <city>Kalmar</city>
        <zip>39185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Obsterics and Gynecology,</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Nielsen HJ. Detrimental effects of perioperative blood transfusion. Br J Surg. 1995 May;82(5):582-7. Review.</citation>
    <PMID>7613921</PMID>
  </reference>
  <reference>
    <citation>Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost. 1993 Aug 2;70(2):238-40.</citation>
    <PMID>8236125</PMID>
  </reference>
  <reference>
    <citation>Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999 Jun;57(6):1005-32. Review.</citation>
    <PMID>10400410</PMID>
  </reference>
  <reference>
    <citation>Gai MY, Wu LF, Su QF, Tatsumoto K. Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial. Eur J Obstet Gynecol Reprod Biol. 2004 Feb 10;112(2):154-7.</citation>
    <PMID>14746950</PMID>
  </reference>
  <reference>
    <citation>Johansson T, Pettersson LG, Lisander B. Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients. Acta Orthop. 2005 Jun;76(3):314-9.</citation>
    <PMID>16156456</PMID>
  </reference>
  <reference>
    <citation>Abu-Rustum NR, Richard S, Wilton A, Lev G, Sonoda Y, Hensley ML, Gemignani M, Barakat RR, Chi DS. Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival. Gynecol Oncol. 2005 Nov;99(2):320-6. Epub 2005 Aug 2.</citation>
    <PMID>16061278</PMID>
  </reference>
  <reference>
    <citation>Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962 Feb;51(2):224-32.</citation>
    <PMID>21936146</PMID>
  </reference>
  <reference>
    <citation>Brecher ME, Monk T, Goodnough LT. A standardized method for calculating blood loss. Transfusion. 1997 Oct;37(10):1070-4.</citation>
    <PMID>9354828</PMID>
  </reference>
  <reference>
    <citation>Johansson T, Lisander B, Ivarsson I. Mild hypothermia does not increase blood loss during total hip arthroplasty. Acta Anaesthesiol Scand. 1999 Nov;43(10):1005-10.</citation>
    <PMID>10593462</PMID>
  </reference>
  <reference>
    <citation>Zohar E, Fredman B, Ellis MH, Ifrach N, Stern A, Jedeikin R. A comparative study of the postoperative allogeneic blood-sparing effects of tranexamic acid and of desmopressin after total knee replacement. Transfusion. 2001 Oct;41(10):1285-9.</citation>
    <PMID>11606830</PMID>
  </reference>
  <reference>
    <citation>Dolan S, Fitch M. The management of venous thromboembolism in cancer patients. Br J Nurs. 2007 Nov 22-Dec 12;16(21):1308-12. Review.</citation>
    <PMID>18073666</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2008</study_first_submitted>
  <study_first_submitted_qc>August 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2008</study_first_posted>
  <last_update_submitted>June 26, 2012</last_update_submitted>
  <last_update_submitted_qc>June 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Linkoeping</investigator_affiliation>
    <investigator_full_name>Preben Kjolhede</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Tumor of ovary</keyword>
  <keyword>Surgical blood loss</keyword>
  <keyword>Postoperative blood loss</keyword>
  <keyword>Preventive therapy</keyword>
  <keyword>Thromboembolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

